drugset
drugset / Trial / NCT06470464

Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor

NCT06470464 ↗

Phase 2 Completed 20 enrolled Shandong First Medical University
NaSingle-groupOpen-labelTreatment

Summary

Remarkable progress has been made in treating germ-cell tumor (GCT) through the use of platinum-based regimens. However, part of yolk sac tumor (YST) with cisplatin resistance or recurrence is nevertheless prone to relapse after second-line treatment. This leaves a gap in effective treatment, which needs to be filled by novel therapeutic approaches. This paper is the first one to report the treatment combining thalidomide with nab-paclitaxel, gemcitabine, and epirubicin (T-TGA) for children with repeated relapsed or refractory yolk sac tumor (rrrYST).

Timeline

Start
2021-11-11
Primary completion
2024-06-16
Completion
2024-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Epirubicin Small molecule — —
Subject Gemcitabine Small molecule — —
Subject Nab-paclitaxel Small molecule — —
Subject Thalidomide Other / unclassified 1.5 mg/kg Oral
Subject Thalidomide Other / unclassified 2.5 mg/kg Oral

Indications

yolk sac tumor